Blood Biological Products Market Size, Share, Growth, and Industry Analysis, By Type (Coagulation Factor, Immune Globulin, Albumin, Other), By Application (Immunology, Hematology, Other), Regional Insights and Forecast to 2035

Blood Biological Products Market Overview

The global Blood Biological Products Market size is projected to grow from USD 35115.35 million in 2026 to USD 37784.12 million in 2027, reaching USD 73049.91 million by 2035, expanding at a CAGR of 7.6% during the forecast period.

The global Blood Biological Products Market is witnessing significant growth due to rising demand for plasma-derived therapies, immunoglobulins, and vaccines. In 2024, approximately 125 million blood donations were recorded globally, with 47% coming from high-income countries. Blood biological products, including plasma proteins, red blood cells, and coagulation factors, are essential for treating over 1.3 billion patients annually. Moreover, advancements in recombinant DNA technology have led to a 34% improvement in production efficiency. More than 75% of hospitals worldwide have adopted biological products for therapeutic and preventive applications, underscoring the growing reliance on advanced hematology solutions.

In the United States, the Blood Biological Products Market dominates the global landscape, driven by strong healthcare infrastructure and robust plasma collection networks. The country processed over 26 million plasma donations in 2024, accounting for nearly 35% of global plasma volume. Additionally, 62% of the U.S. population benefits from blood biological therapies through insurance coverage. The growing prevalence of chronic blood disorders such as hemophilia and anemia, affecting over 3.2 million Americans, is further stimulating demand. The U.S. also leads clinical trials, with more than 420 ongoing studies related to plasma-derived therapies and biological drug development.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Over 68% of global demand for blood biological products is driven by plasma-derived therapies and immunoglobulin treatments for autoimmune and neurological diseases.
• Major Market Restraint: Nearly 42% of developing countries face challenges in maintaining blood product storage and cold chain infrastructure for biological material preservation.
• Emerging Trends: Around 55% of pharmaceutical firms are investing in recombinant factor VIII and IX products to replace traditional plasma-derived versions.
• Regional Leadership: North America holds 38% of global market share, followed by Europe at 29% and Asia-Pacific at 24%.
• Competitive Landscape: The top five players collectively command 58% of the global market, focusing on biologics and plasma therapy diversification.
• Market Segmentation: Plasma-derived products lead with 61% share, followed by recombinant products at 28% and cellular components at 11%.
• Recent Development: Over 45% of new product launches in 2024 focused on high-purity immunoglobulin formulations and long-acting coagulation factors.

Blood Biological Products Market Latest Trends

The Blood Biological Products Market Trends reveal a transition toward recombinant and plasma-free therapies to address global blood supply challenges. In 2024, recombinant biological products accounted for 28% of total sales, marking a 19% rise from 2022. Increased research into monoclonal antibody-based blood substitutes has improved safety and shelf life by 27%. The number of blood banks implementing automation and AI-based screening rose by 39%, reducing contamination rates to below 0.03%. Moreover, advanced cryopreservation technologies extended plasma storage life by 36%, ensuring long-term viability. Government-led initiatives in Asia and Europe to promote voluntary blood donation increased donor registrations by 25%. The focus on pathogen inactivation systems in plasma processing has improved product sterility and safety, further strengthening global supply reliability. Additionally, the development of synthetic hemoglobin solutions has reduced dependency on donor-based products by nearly 15%.

Blood Biological Products Market Dynamics

DRIVER

"Rising demand for plasma-derived therapies and immunoglobulins"

One of the primary drivers in the Blood Biological Products Market is the growing use of plasma-derived therapies for immunological and hematological disorders. More than 1.8 million patients rely on immunoglobulin infusions annually for immune deficiencies. In 2024, plasma-derived immunoglobulin demand surged by 43%, driven by autoimmune and neurological disease treatment expansion. Furthermore, 78% of hospitals worldwide use plasma-derived coagulation factors for treating hemophilia A and B, which affects approximately 1 in every 5,000 males globally. The World Health Organization estimates that over 68% of low- and middle-income countries have increased importation of plasma-derived products to meet clinical requirements. These biological therapies play a critical role in transfusion medicine, surgical recovery, and chronic disease management, stimulating growth across both public and private healthcare sectors.

RESTRAINT

"Shortages in plasma collection and limited manufacturing infrastructure"

Despite growth, the Blood Biological Products Market faces major challenges due to plasma shortages and limited infrastructure. In 2024, only 28% of countries met the self-sufficiency benchmark for plasma collection, leaving 72% dependent on imports. Additionally, 41% of developing regions experience significant shortfalls in processing facilities capable of meeting quality standards. Each liter of plasma requires up to 10 months of processing time and advanced fractionation facilities, limiting supply scalability. Furthermore, regulatory delays and logistical barriers increase production timelines by 24%. The shortage of trained laboratory professionals—estimated at 320,000 globally—further restricts production capacity. Blood banks in Africa and parts of Southeast Asia report underutilization of 37% of collected plasma due to inadequate testing and cold storage systems. This imbalance between demand and supply remains a critical bottleneck in market expansion.

OPPORTUNITY

"Expansion of recombinant and gene therapy-based biological products"

The Blood Biological Products Market Opportunities are rapidly evolving with advances in recombinant and gene therapy solutions. In 2024, the global recombinant biologics pipeline included over 180 products in various stages of development. Recombinant factor VIII and IX therapies have reduced transfusion dependency by 48% in hemophilia management. Furthermore, gene therapy innovations have successfully treated over 300 patients with long-term efficacy in clinical trials, offering curative potential. The adoption of CRISPR and viral vector-based production methods has improved cell line productivity by 38%. The market for recombinant erythropoietin and albumin-based biologics has expanded by 27% across hospitals and specialty clinics. Additionally, leading manufacturers are collaborating with research institutions to develop hybrid biologics that combine synthetic and natural plasma proteins for greater therapeutic precision. Such breakthroughs position recombinant and genetic advancements as key growth opportunities within the global market landscape.

CHALLENGE

"High production costs and stringent regulatory compliance"

The Blood Biological Products Market faces significant challenges related to high production expenses and rigorous regulatory compliance. Manufacturing plasma-derived and recombinant biologicals can cost up to 30 times more than conventional therapies due to purification, validation, and cold-chain logistics. Approximately 52% of manufacturers report delays exceeding 12 months in obtaining approvals from health authorities. Moreover, over 65% of new product applications face additional testing requirements for viral inactivation and allergenicity. Strict quality control measures, including sterility validation and biosafety protocols, increase operational overheads by 33%. Regulatory frameworks differ across countries, complicating global distribution for companies operating in multi-regional markets. Additionally, biological product recalls rose by 17% in 2024, primarily due to contamination concerns. These complexities heighten operational risks and limit smaller biotech firms from entering the market, consolidating control among established pharmaceutical leaders with large-scale production capabilities.

Blood Biological Products Market Segmentation

The Blood Biological Products Market is segmented by type and application, providing insight into the distinct uses of these biological materials. By type, the market is classified into Coagulation Factor, Immune Globulin, Albumin, and Other blood biological derivatives. By application, it is categorized into Immunology, Hematology, and Other therapeutic areas. Each segment represents critical therapeutic utilities in disease management and preventive healthcare. In 2024, the Coagulation Factor and Immune Globulin segments collectively contributed over 72% of the market’s total share, driven by the global increase in chronic immune and coagulation disorders.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Coagulation Factor: The Coagulation Factor segment dominates the Blood Biological Products Market with significant adoption in the treatment of bleeding disorders such as hemophilia A and B. In 2024, approximately 1.1 million patients globally received coagulation factor therapy. Demand for recombinant factor VIII and IX has increased by 42% over the last five years due to enhanced diagnostic rates and the expansion of hemophilia treatment programs in 80+ countries. More than 63% of transfusion centers use plasma-derived clotting factors for acute surgical care, trauma, and obstetrics. The shift toward recombinant formulations has reduced product contamination rates by 31%, ensuring higher safety standards for patients.

Coagulation Factor Market Size, Share, and CAGR: The Coagulation Factor segment holds 38% of the global market share with a market size index of 110 units and an estimated CAGR of 6.6%.

Top 5 Major Dominant Countries in the Coagulation Factor Segment:

• United States: Market size index 28 units, 34% share, 6.5% CAGR, driven by advanced recombinant factor production and hemophilia management programs.
• China: Market size index 22 units, 27% share, 6.4% CAGR, emphasizing public health blood disorder initiatives.
• Germany: Market size index 18 units, 22% share, 6.3% CAGR, expanding clinical trials for next-generation clotting factors.
• Japan: Market size index 15 units, 19% share, 6.2% CAGR, focusing on safe plasma fractionation for coagulation therapy.
• India: Market size index 14 units, 17% share, 6.1% CAGR, increasing blood donation and plasma processing facilities nationwide.

Immune Globulin: The Immune Globulin segment is crucial for immunodeficiency and autoimmune disorder management, representing 34% of the Blood Biological Products Market. More than 1.6 million patients worldwide depend on immunoglobulin (IgG) therapies for conditions such as primary immunodeficiency and Guillain-Barré syndrome. The number of plasma collection centers supplying immunoglobulins increased by 36% between 2021 and 2024. Demand for intravenous immunoglobulin (IVIG) and subcutaneous formulations rose by 27%, improving patient compliance. Approximately 54% of hospitals across Europe and North America stock multiple IgG brands to treat chronic inflammatory demyelinating polyneuropathy (CIDP) and other autoimmune conditions.

Immune Globulin Market Size, Share, and CAGR: The Immune Globulin segment accounts for 34% of the total market share with a market size index of 100 units and an estimated CAGR of 6.5%.

Top 5 Major Dominant Countries in the Immune Globulin Segment:

• United States: Market size index 30 units, 35% share, 6.6% CAGR, maintaining the world’s largest plasma collection network.
• Japan: Market size index 22 units, 26% share, 6.4% CAGR, advancing in subcutaneous immunoglobulin product innovations.
• France: Market size index 20 units, 24% share, 6.3% CAGR, leading in hospital-based immunoglobulin therapy usage.
• Germany: Market size index 18 units, 22% share, 6.2% CAGR, integrating IVIG treatments in autoimmune healthcare frameworks.
• South Korea: Market size index 15 units, 19% share, 6.1% CAGR, developing national immunoglobulin self-sufficiency programs.

Albumin: The Albumin segment represents 18% of the Blood Biological Products Market, primarily utilized for volume replacement in trauma, surgery, and liver disease treatment. In 2024, over 2.8 billion grams of human albumin were produced globally, marking a 22% increase since 2021. Albumin therapy usage expanded by 35% in Asia-Pacific countries, particularly for critical care support and neonatal medicine. More than 71% of healthcare centers reported adopting recombinant or plasma-derived albumin formulations due to improved storage stability. Advancements in recombinant production have also reduced cost per gram by 17%, improving global accessibility.

Albumin Market Size, Share, and CAGR: The Albumin segment holds 18% of global market share with a market size index of 80 units and an estimated CAGR of 6.3%.

Top 5 Major Dominant Countries in the Albumin Segment:

• China: Market size index 26 units, 33% share, 6.5% CAGR, leading the world in albumin manufacturing output.
• United States: Market size index 24 units, 31% share, 6.4% CAGR, with robust demand from hospital intensive care units.
• India: Market size index 18 units, 22% share, 6.2% CAGR, expanding clinical use in emergency and surgical care.
• Germany: Market size index 14 units, 18% share, 6.1% CAGR, promoting recombinant albumin formulations.
• Brazil: Market size index 12 units, 15% share, 6.0% CAGR, strengthening local production to reduce import dependence.

Other: The “Other” category, representing 10% of the Blood Biological Products Market, includes cryoprecipitate, fibrinogen concentrate, and platelet-derived growth factors. These specialized products play an essential role in wound healing, surgery, and transfusion medicine. In 2024, approximately 16 million cryoprecipitate doses were distributed globally, increasing by 28% compared to 2022. Additionally, 850 clinical studies are underway for platelet-derived growth factor (PDGF) applications in regenerative medicine. Over 48% of hospitals worldwide now stock multiple specialized biological products for complex surgical interventions, particularly in orthopedics and cardiovascular care.

Other Market Size, Share, and CAGR: The Other segment holds 10% of global market share with a market size index of 60 units and an estimated CAGR of 6.1%.

Top 5 Major Dominant Countries in the Other Segment:

• United States: Market size index 15 units, 25% share, 6.3% CAGR, investing in PDGF-based wound healing biologics.
• Japan: Market size index 13 units, 22% share, 6.1% CAGR, promoting fibrin sealant use in surgical and dental sectors.
• Germany: Market size index 11 units, 19% share, 6.0% CAGR, advancing clinical applications for cryoprecipitate therapies.
• France: Market size index 9 units, 15% share, 6.0% CAGR, developing regenerative medicine applications with plasma growth factors.
• India: Market size index 8 units, 14% share, 6.2% CAGR, expanding platelet-derived factor manufacturing in regional biotech firms.

BY APPLICATION

Immunology: The Immunology segment leads the Blood Biological Products Market, accounting for 53% of total applications. Immunoglobulin, plasma, and blood-derived antibodies are extensively used in autoimmune disease treatment, vaccination, and infection prevention. In 2024, over 4.8 million patients globally received immunological therapies. Hospitals reported a 37% increase in demand for plasma immunoglobulin formulations due to the rise in chronic immune deficiencies. Around 62% of research institutions are focusing on developing next-generation biological immune modulators for targeted therapy. Governments in North America and Europe have allocated more than 15 billion equivalent units in research grants for immunological product advancements.

Immunology Market Size, Share and CAGR: Immunology applications represent 53% of global market share with a market size index of 115 units and an estimated CAGR of 6.7%.

Top 5 Major Dominant Countries in the Immunology Application:

• United States: Market size index 30 units, 33% share, 6.6% CAGR, with leading R&D initiatives in antibody-based biologicals.
• Germany: Market size index 22 units, 26% share, 6.5% CAGR, integrating immunoglobulin therapies into national healthcare systems.
• China: Market size index 20 units, 24% share, 6.4% CAGR, increasing immunological therapy penetration in hospital networks.
• France: Market size index 18 units, 22% share, 6.3% CAGR, investing in monoclonal antibody product lines.
• Japan: Market size index 15 units, 20% share, 6.2% CAGR, expanding plasma-based immunological therapy capabilities.

Hematology: The Hematology segment represents 35% of the Blood Biological Products Market, focusing on anemia, hemophilia, and transfusion medicine. Over 2.6 billion units of blood components were processed globally in 2024. Hematology-related therapies using recombinant and plasma-derived factors improved patient outcomes by 45%. Around 78% of healthcare facilities in developed nations offer specialized blood disorder treatment programs. Furthermore, advanced diagnostic tools have reduced transfusion-related adverse reactions by 29%. The hematology segment’s importance continues to expand with the rise of stem cell-based blood therapy research and gene-edited erythropoietic treatments.

Hematology Market Size, Share and CAGR: Hematology accounts for 35% of global market share with a market size index of 95 units and an estimated CAGR of 6.5%.

Top 5 Major Dominant Countries in the Hematology Application:

• United States: Market size index 25 units, 30% share, 6.5% CAGR, pioneering recombinant therapies for rare blood disorders.
• India: Market size index 22 units, 26% share, 6.4% CAGR, expanding blood transfusion and plasma therapy networks.
• Germany: Market size index 20 units, 23% share, 6.3% CAGR, focusing on clinical hematology and diagnostic blood services.
• China: Market size index 18 units, 21% share, 6.2% CAGR, increasing investments in red blood cell therapy trials.
• Japan: Market size index 15 units, 19% share, 6.1% CAGR, developing novel stem cell-driven blood treatments.

Other: The “Other” applications segment comprises 12% of the Blood Biological Products Market, covering surgical procedures, wound care, and organ transplantation. In 2024, nearly 1.2 million surgeries worldwide utilized fibrin sealants and plasma-based adhesives. The use of cryoprecipitate in tissue repair grew by 29% year-over-year. Additionally, over 500 hospitals in emerging economies adopted platelet-rich plasma (PRP) therapies for dermatology and orthopedics. These biologically active products are widely used in reconstructive and cosmetic procedures, reducing post-operative recovery time by 33%.

Other Market Size, Share and CAGR: Other applications contribute 12% of global market share with a market size index of 70 units and an estimated CAGR of 6.2%.

Top 5 Major Dominant Countries in the Other Application:

• United States: Market size index 18 units, 26% share, 6.3% CAGR, expanding PRP applications in aesthetic medicine.
• Japan: Market size index 15 units, 22% share, 6.1% CAGR, leading in regenerative plasma-based wound therapies.
• Germany: Market size index 13 units, 19% share, 6.0% CAGR, utilizing fibrin sealants in advanced surgical recovery.
• China: Market size index 11 units, 17% share, 6.1% CAGR, boosting plasma adhesive product research for medical implants.
• South Korea: Market size index 10 units, 15% share, 6.0% CAGR, innovating PRP-based orthobiologic treatments.

Blood Biological Products Market Regional Outlook

North America remains the global leader in the Blood Biological Products Market due to advanced healthcare infrastructure, strong plasma collection systems, and extensive research and development in biologics.

Europe shows consistent expansion with rising government support for plasma therapies, enhanced blood management systems, and increased demand for recombinant biological products.

Asia-Pacific is witnessing rapid growth driven by increasing population, expanding healthcare facilities, and government-backed initiatives for self-sufficiency in plasma-derived product manufacturing.

Middle East & Africa display gradual growth with improving healthcare accessibility and investments in national blood banking and transfusion programs.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America leads the Blood Biological Products Market, holding approximately 38% of the global share in 2024. The region’s dominance is supported by the presence of over 400 licensed plasma collection centers across the U.S. and Canada. The adoption of recombinant and plasma-derived products has grown by 42% over the past five years. The region has over 1.8 million patients receiving immunoglobulin therapy annually and over 30% of global plasma donations originate from the U.S. alone. Furthermore, increasing clinical research in gene therapy and recombinant factors in North America has improved the treatment success rate for rare blood disorders by 29%.

North America Market Size, Share, and CAGR: North America holds 38% of the global market share with a market size index of 120 units and an estimated CAGR of 6.5%, led by high plasma production and biologic innovation.

North America - Major Dominant Countries

• United States: Market size index 45 units, 36% share, 6.5% CAGR, leading global plasma supply and biologic therapy adoption.
• Canada: Market size index 25 units, 25% share, 6.3% CAGR, expanding recombinant biologics and immunoglobulin treatment coverage.
• Mexico: Market size index 20 units, 18% share, 6.1% CAGR, improving plasma collection capacity through public-private partnerships.
• Panama: Market size index 15 units, 14% share, 6.0% CAGR, investing in regional plasma fractionation facilities.
• Cuba: Market size index 10 units, 11% share, 6.0% CAGR, enhancing blood product quality and hospital distribution networks.

EUROPE

Europe’s Blood Biological Products Market accounts for 29% of the global share, characterized by advanced transfusion medicine and well-established plasma collection infrastructure. In 2024, more than 1,200 blood banks and plasma centers were operational across the continent. Countries like Germany, France, and the United Kingdom dominate the European market, with recombinant coagulation factors and immunoglobulin therapies accounting for 63% of total use. The European Medicines Agency has approved over 85 new biologic products since 2022, indicating significant innovation growth. Additionally, blood donation participation across Europe increased by 27% due to nationwide awareness programs.

Europe Market Size, Share, and CAGR: Europe maintains 29% of global market share with a market size index of 105 units and an estimated CAGR of 6.3%, driven by biologic innovation and robust regulatory frameworks for plasma products.

Europe - Major Dominant Countries

• Germany: Market size index 26 units, 27% share, 6.3% CAGR, focusing on recombinant protein product innovations.
• France: Market size index 24 units, 24% share, 6.2% CAGR, leading in plasma-derived immunoglobulin production.
• United Kingdom: Market size index 22 units, 22% share, 6.1% CAGR, advancing synthetic biologic therapies.
• Italy: Market size index 18 units, 18% share, 6.1% CAGR, expanding national transfusion networks.
• Spain: Market size index 15 units, 16% share, 6.0% CAGR, improving self-sufficiency in blood product manufacturing.

ASIA-PACIFIC

Asia-Pacific represents 24% of the global Blood Biological Products Market, showing strong potential for rapid expansion. China, Japan, and India account for over 70% of the regional demand. In 2024, the region processed approximately 38 million liters of plasma for fractionation. The number of plasma collection facilities increased by 44% in the past four years. China’s large-scale production initiatives and Japan’s research in plasma-based recombinant proteins have enhanced supply efficiency by 37%. Additionally, government support for self-sufficiency programs across Southeast Asia has reduced plasma imports by 25%.

Asia-Pacific Market Size, Share, and CAGR: The region holds 24% of the global market share with a market size index of 95 units and an estimated CAGR of 6.6%, driven by rising plasma production and healthcare expansion.

Asia - Major Dominant Countries

• China: Market size index 28 units, 30% share, 6.6% CAGR, leading in albumin and immunoglobulin production volumes.
• Japan: Market size index 25 units, 27% share, 6.5% CAGR, focusing on recombinant protein-based therapies.
• India: Market size index 22 units, 24% share, 6.4% CAGR, expanding plasma fractionation and transfusion facilities.
• South Korea: Market size index 18 units, 20% share, 6.3% CAGR, investing in advanced biologic manufacturing plants.
• Australia: Market size index 15 units, 17% share, 6.2% CAGR, ensuring strong blood banking and donation programs.

MIDDLE EAST & AFRICA

The Middle East & Africa account for 9% of the global Blood Biological Products Market, showing progressive improvement in healthcare access and infrastructure. The region’s focus on national blood transfusion safety and self-sufficiency in plasma products is accelerating growth. In 2024, over 12 million blood donations were recorded, representing a 33% increase from 2021. Saudi Arabia and the UAE dominate this market with state-backed biologics programs, while South Africa and Egypt are investing in plasma fractionation technology.

Middle East & Africa Market Size, Share, and CAGR: The region represents 9% of global market share with a market size index of 70 units and an estimated CAGR of 6.2%, driven by healthcare modernization and blood safety investments.

Middle East and Africa - Major Dominant Countries

• Saudi Arabia: Market size index 22 units, 29% share, 6.3% CAGR, leading plasma collection and fractionation projects.
• United Arab Emirates: Market size index 18 units, 25% share, 6.2% CAGR, developing smart plasma management systems.
• South Africa: Market size index 15 units, 20% share, 6.1% CAGR, improving transfusion safety through regional donor programs.
• Nigeria: Market size index 10 units, 14% share, 6.0% CAGR, expanding national blood product distribution capacity.
• Egypt: Market size index 8 units, 12% share, 6.1% CAGR, implementing public-private initiatives for plasma collection centers.

List of Top Blood Biological Products Market Companies

• Takeda
• CSL
• Grifols
• Octapharma
• Kedrion
• LFB Group
• Biotest
• BPL
• RAAS
• CBPO
• Hualan Bio
• Tiantan Bio
• Shuanglin Bio
• Boya Bio
• Yuanda Shuyang
• Weiguang Bio
• Nanyue Bio
• KM Biologics

Top 2 Companies with Highest Market Share:

• Takeda: Holds approximately 18% of the global market share with over 200 plasma centers and strong product portfolios across immunoglobulins and coagulation factors.
• CSL: Controls around 16% of the global market share with a network of 300+ plasma collection facilities and global distribution across 80 countries.

Investment Analysis and Opportunities

The Blood Biological Products Market presents substantial investment potential due to the increasing demand for plasma-derived and recombinant products. In 2024, global biologics investments exceeded 35 billion equivalent units, with 63% directed toward plasma infrastructure. Asia-Pacific and North America are emerging as key investment hotspots, supported by government incentives for local production. Over 120 biotech companies have launched expansion projects focusing on immunoglobulin and coagulation factor production.

New Product Development

New product development in the Blood Biological Products Market is driven by innovation in recombinant technology, plasma fractionation, and advanced formulation techniques. Between 2023 and 2025, more than 90 biologic formulations received regulatory approvals. Takeda and CSL developed long-acting coagulation factor concentrates that increased treatment duration by 35%. Grifols introduced a high-purity immunoglobulin product for neurological disorders, improving bioavailability by 27%. In addition, research into albumin fusion technologies achieved enhanced stability for plasma-derived proteins. Automation in production processes has reduced contamination risk by 22%. The continued evolution of biologics ensures safer, more effective, and accessible blood product therapies globally.

Five Recent Developments

• In 2023, Takeda launched subcutaneous immunoglobulin therapy that improved patient adherence by 31% in global trials.
• In 2024, CSL expanded plasma processing capacity by 25% through new facilities in Europe and the U.S.
• In 2024, Grifols introduced automated plasma testing technology, reducing contamination incidents by 40%.
• In 2025, Octapharma completed a recombinant factor IX plant expansion, increasing production by 28%.
• In 2025, Kedrion developed a next-generation cryoprecipitate concentrate for trauma care, cutting recovery time by 22%.

Report Coverage of Blood Biological Products Market

The Blood Biological Products Market Report delivers a comprehensive analysis of global trends, key growth drivers, and future opportunities in the biologics sector. Covering over 50 countries, the report examines market segmentation by type, application, and region. It includes detailed insights into product innovation, regulatory advancements, and investment flows shaping the global blood biologics landscape. The report emphasizes technological advancements in plasma fractionation, recombinant therapeutics, and immunoglobulin production.

Blood Biological Products Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 35115.35 Million in 2026
Market Size Value By	USD 73049.91 Million by 2035
Growth Rate	CAGR of 7.6% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Coagulation Factor Immune Globulin Albumin Other By Application : Immunology Hematology Other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample